Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have acute lymphoblastic leukemia (ALL) or lymphoma that has come back or stopped responding to treatment, and you have already tried at least two different treatments that did not work well enough.
- Your cancer has tested positive for a protein called CD19, based on a recent tissue or blood sample.
- You are between 1 and 17 years old.
- You are well enough to carry out some daily activities, as measured by a standard health scoring tool appropriate for your age (confirm with trial site).
- Your liver, kidneys, and blood cell counts are within acceptable ranges based on recent lab tests (confirm with trial site).
- It has been at least 2 weeks (or a short enough time based on the last treatment used) since your last cancer treatment, before the blood collection procedure begins.
- A parent or legal guardian is able and willing to read and sign a consent form agreeing to take part.
Who may not be able to join:
- You have had a stem cell transplant using your own cells within the last 6 weeks before the planned treatment.
- You have previously received CAR-T cell therapy outside of this trial.
- Your cancer has spread to the brain or the fluid surrounding the brain and spinal cord.
- You have another active cancer (other than certain minor skin cancers or very early-stage cancers that are not spreading).
- You have an active HIV infection.
- You have another serious illness that is not under control, such as a serious infection, heart problems, breathing problems, or significant mental health conditions that could affect your ability to take part.
- You are pregnant or breastfeeding.
- There is evidence of a specific type of bone marrow disorder called myelodysplasia, found on a bone marrow test taken before starting this trial.
- You have an active hepatitis B or hepatitis C infection, shown through a blood test.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Pamela Lee, MD, The University of Hong Kong
Phone: 852-35136049
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Complete response rate (CRR) for ALL and Overall response rate (ORR) for lymphoma; Incidence and severity of adverse events
Can't join this trial?
Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.